Kura Oncology (KURA) Misses Q4 EPS by 66c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts KURA Hot Sheet
Join SI Premium – FREE
Kura Oncology (NASDAQ: KURA) reported Q4 EPS of ($0.92), $0.66 worse than the analyst estimate of ($0.26). Revenue for the quarter came in at $17.34 million versus the consensus estimate of $74.52 million.
For earnings history and earnings-related data on Kura Oncology (KURA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- Sixth Street Specialty Lending (TSLX) Reports In-Line Q3 EPS
- Tarsus Pharmaceuticals, Inc. (TARS) Misses Q3 EPS by 1293c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
